SCHEMBL14601307

SCHEMBL14601307

Cc1ccccc1-c1ccc(CB=O)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 8/20 0.40
CYP11B2 P19099 7/20 0.40
IDO1 P14902 1/20 0.39
METAP2 P50579 1/20 0.39
PDCD1 Q15116 2/20 0.39
CD274 Q9NZQ7 2/20 0.39
CYP1A2 P05177 4/20 0.37
CYP2C19 P33261 4/20 0.37
CYP2D6 P10635 3/20 0.37
CLK4 Q9HAZ1 3/20 0.37
TP53 P04637 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
HIF1A Q16665 1/20 0.37
FFAR1 O14842 1/20 0.36
CYP3A4 P08684 3/20 0.36
HSD17B10 Q99714 2/20 0.36
ALDH1A1 P00352 2/20 0.36
ALOX15 P16050 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16801759 0.80 NPC1 (0.44) CYP11B1CYP11B2IDO1METAP2PDCD1
SCHEMBL1998938 0.79 PDCD1 (0.47) CYP11B1CYP11B2IDO1METAP2PDCD1
SCHEMBL12568272 0.79 CYP11B1 (0.43) CYP11B1CYP11B2IDO1METAP2PDCD1
SCHEMBL5991772 0.79 CYP11B1 (0.43) CYP11B1CYP11B2IDO1METAP2PDCD1
Bromide SCHEMBL2002010 0.78 CYP11B1 (0.42) CYP11B1CYP11B2IDO1METAP2PDCD1
SCHEMBL26052512 0.78 SMN1; SMN2 (0.48) CYP11B1CYP11B2IDO1METAP2PDCD1
SCHEMBL18729757 0.76 CYP11B1 (0.44) CYP11B1CYP11B2IDO1METAP2PDCD1
SCHEMBL18814933 0.76 S1PR1 (0.41) CYP11B1CYP11B2IDO1METAP2PDCD1
Bromide SCHEMBL27697063 0.75 CYP11B1 (0.40) CYP11B1CYP11B2IDO1METAP2PDCD1
SCHEMBL30873954 0.75 FFAR1 (0.58) FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070021346-A1 N-terminally modified GLP-1 receptor modulators BRISTOL-MYERS SQUIBB COMPANY 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021346-A1 N-terminally modified GLP-1 receptor modulators GLP1R, GIPR, IAPP CYP11B1 3426/4885CYP11B2 3592/4885IDO1 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.